SEC Filing Summary: Leap Therapeutics, Inc. (LPTX)
Business Context and Reporting Period
This Form 8-K was filed by Leap Therapeutics, Inc. on March 17, 2025, reporting an event that occurred on March 12, 2025. The Company is a Delaware corporation with its principal executive offices in Cambridge, MA, and its common stock trades on the Nasdaq Capital Market under the symbol "LPTX". The filing addresses a regulatory notice regarding the Company's continued listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a listing deficiency notice and does not contain financial performance data for the current or prior periods.
Material Changes and Listing Status
On March 12, 2025, the Company received a "Closing Bid Price Deficiency Letter" from Nasdaq. The notice states that for the last 30 consecutive business days, the closing bid price of the Company's common stock has been below the minimum requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). This is a notice of deficiency and does not currently result in delisting or affect trading.
Outlook, Compliance Plan, and Risks
- Compliance Period: The Company has 180 days, until September 8, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
- Extension Eligibility: If the Company meets other listing standards (excluding the bid price) by September 8, 2025, it may be eligible for an additional 180-day compliance period to cure the deficiency, potentially through a reverse stock split.
- Management Commentary: Management intends to monitor the stock price closely and consider all available options to regain compliance.
- Risks: The Company explicitly states there can be no assurance that it will be able to regain compliance during the initial 180-day period, any additional period, or at all.
Key Facts for Investor Verification
- Verify the current closing bid price of LPTX shares to assess the severity of the deficiency.
- Monitor the Company's stock price trajectory over the next 10 consecutive business days to determine if immediate compliance is possible.
- Review upcoming filings for any announcement of a reverse stock split or other capital structure changes intended to cure the deficiency.
- Confirm the Company's market value of publicly held shares to assess eligibility for the potential 180-day extension period.